Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT03972306
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸University of South Florida School of Medicine Morsani Center for Advanced Health Care, Tampa, Florida, United States
Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4138
- Registration Number
- NCT03969212
- Locations
- 🇯🇵
Medical corporation Seijinkai Takei Clinic, Tsuru, Japan
🇯🇵Gushiken-Cardiology and Internal medicine, Urasoe, Japan
🇯🇵Uranishi Clinic, Urasoe, Japan
Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT03959332
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT03943550
- Locations
- 🇲🇩
ARENSIA Phase 1 Unit- Spitalul Clinic Republican Location, Chisinau, Moldova, Republic of
🇺🇸Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇬🇪The Research Institute of Clinical Medicine, Tbilisi, Georgia
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03923738
- Locations
- 🇨🇭
Universitätsspital Basel; Rheumatologie, Basel, Switzerland
🇨🇭Inselspital Bern; Rheumatologie; Klinische Immunologie und Allergologie, Bern, Switzerland
A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 101
- Registration Number
- NCT03922997
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing City, China
🇨🇳Sichuan Cancer Hospital, Chengdu City, China
🇨🇳Harbin Medical University Tumor Hospital; Department of Surgery; Pharmacy, Harbin, China
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT03922477
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Yale, New Haven, Connecticut, United States
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT03920865
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation Inc., San Antonio, Texas, United States
The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03912350
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 83
- Registration Number
- NCT03875079
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇫🇷Centre Eugene Marquis; Service d'oncologie, Rennes, France
🇫🇷Institut Gustave Roussy; Dermatologie, Villejuif, France